Merck Serono
Diatech Pharmacogenetics, Merck KGaA Expand RAS Biomarker Testing Pact in Middle East, Africa
The companies are collaborating to improve access to biomarker testing to inform the use of targeted therapies in colorectal cancer across the region.
Merck KGaA Updates Clinical Trial Plans for Several Precision Oncology Candidates
The Darmstadt, Germany-based drugmaker outlined its strategy for advancing an ATR inhibitor, a PARP inhibitor, and an antibody-drug conjugate.
FDA Approves Merck KGaA's Tepmetko for Non-Small Cell Lung Cancer With METex14 Alterations
The drug received accelerated approval for metastatic non-small cell lung cancers with MET exon 14 skipping alterations based on the Phase II VISION trial.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Bavencio Presents Potentially Curative Option for Patients With Rare PD-L1-Expressing Gestational Tumors
In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.